Sino Gene surges as BTIG sees promise in co's gene therapy trials

Sio Gene Therapies

15/06/2021 11:36

** Drug developer's shares  SIOX.O  surge 12.3% premarket,
set to open at a seven-week high of $2.82
    ** Brokerage BTIG starts with "buy" rating and PT of $8, in
line with median PT as per Refinitiv data
    ** BTIG cheers co's three clinical-stage gene therapy
programs that it licensed from partners
    ** Says progress achieved in each program should support
SIOX's continued growth into a strong gene therapy pure play
    ** In Dec. SIOX reported positive six-month follow-up data
its gene therapy for GM1 gangliosidosis  urn:newsml:reuters.com:*:nL4N2IW2IY
    ** GM1 gangliosidosis is an inherited disorder that
progressively destroys nerve cells in brain and spinal cord
    ** Shares set to extend gains to an eighth straight session
nad post theirbest session in four months
    ** Stock down 9.3% YTD, as of last close   

 (Reporting by Susan Mathew in Bengaluru;)
 ((susan.mathew@thomsonreuters.com; +91-80-6287-2704;))
 
((Ghth))